• Wondering whether Illumina at US$166.21 is priced for opportunity or already reflects the story? This article focuses squarely on what the current share price might be implying about value.
• The stock has delivered an 88.6% return over the past year, while being up 23.7% year to date and 14.1% over the past month. This comes even though it has fallen 18.5% over three years and 62.4% over five years, and slipped 1.1% in the last week.
• These moves sit against a backdrop of ongoing attention on Illumina's core sequencing business and broader interest in companies tied to genomics. For investors, that mix of long term share price declines together with a strong 1 year rebound sets the scene for a closer look at what the current valuation might be pricing in.
• Illumina currently has a valuation score of 3 out of 6. The next sections will walk through different valuation methods to see how they compare, before finishing with a broader framework that can help you put all of these numbers in context.

Approach 1: Illumina Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value using a required rate of return.

For Illumina, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about US$913.9 million. Analysts provide explicit forecasts out to 2030, with Simply Wall St extending the path further using its own assumptions. Within that, projected Free Cash Flow for 2030 is US$1.66b, with values between 2026 and 2035 ranging from roughly US$899.5 million to US$2.45b before discounting.

Discounting these projected cash flows back to today gives an estimated intrinsic value of US$247.33 per share under this DCF model. Compared with the current share price of US$166.21, this implies the stock trades at a 32.8% discount to that estimate. On this specific cash flow view, the shares appear undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Illumina is undervalued by 32.8%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Illumina Price vs Earnings

For profitable companies, the P/E ratio is a useful anchor because it connects what you pay for the stock to the earnings the business is currently generating. It helps you quickly see how many dollars of price the market is attaching to each dollar of earnings.

What counts as a "normal" P/E often reflects how the market views a company’s growth potential and risk profile. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher uncertainty tends to align with a lower multiple.

Illumina currently trades on a P/E of 29.48x. That is close to the peer average of 29.26x and below the Life Sciences industry average of 33.86x. Simply Wall St’s proprietary Fair Ratio for Illumina is 21.70x. This Fair Ratio is designed to reflect the kind of P/E you might expect given factors like earnings growth, profit margins, market cap, risks and the company’s industry.

Because it folds these company specific drivers into a single number, the Fair Ratio can be more tailored than a simple comparison with peers or an industry average. With Illumina trading at 29.48x against a Fair Ratio of 21.70x, the shares appear expensive on this P/E lens.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Illumina Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Consider Narratives, which let you attach a clear story about Illumina to specific assumptions for future revenue, earnings and margins. You can then link that story to a Fair Value and compare it with the current share price, all in an easy tool on Simply Wall St's Community page that updates as new news or earnings arrive. For example, one investor might align with a higher Fair Value around US$175.00 based on faster clinical adoption, while another leans toward a lower Fair Value near US$87.05 because of concerns around competition and regulation. Seeing those different Illumina Narratives side by side can help you decide which story you find more convincing before you act.

For Illumina however we will make it really easy for you with previews of two leading Illumina Narratives:

Fair value used in this bullish narrative: US$175.00

Gap to that fair value: about 5.0% below the narrative estimate at the current US$166.21 share price

Revenue growth assumption: 8.35% a year

• Analysts in this camp see clinical adoption, especially in oncology, rare disease and reproductive health, as a key support for recurring consumables revenue and higher earnings over time.
• They include efficiency gains and cost reductions that, combined with consumables mix, could support margin expansion and earnings of about US$1.1b by 2029.
• To align with this view, you would need to be comfortable with Illumina reaching about US$5.6b of revenue and trading on a P/E of around 28.4x in 2029.

Fair value used in this bearish narrative: US$87.05

Gap to that fair value: about 91.0% above the narrative estimate at the current US$166.21 share price

Revenue growth assumption: 4.68% a year

• The bearish group focuses on regulatory pressure, data privacy, and healthcare budget constraints as potential drags on future revenue and margins.
• They highlight competition in sequencing, a concentrated customer base, and geopolitical risks as factors that could limit market reach and weigh on profitability.
• On their numbers, Illumina would reach about US$5.0b of revenue and US$981.6m of earnings by 2029, but on a lower 15.4x P/E, which keeps their fair value well below today’s price.

These two narratives frame the range of analyst expectations quite clearly, from a fair value near US$175.00 at the optimistic end to about US$87.05 at the cautious end. Your own view on Illumina will probably sit somewhere between these stories, depending on how you weigh clinical growth, competition, regulation, and execution risks in your portfolio and time horizon.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Illumina on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Illumina? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.